Your browser doesn't support javascript.
loading
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.
Dierig, A; Hoelscher, M; Schultz, S; Hoffmann, L; Jarchow-MacDonald, A; Svensson, E M; Te Brake, L; Aarnoutse, R; Boeree, M; McHugh, T D; Wildner, L M; Gong, X; Phillips, Ppj; Minja, L T; Ntinginya, N; Mpagama, S; Liyoyo, A; Wallis, R S; Sebe, M; Mhimbira, F A; Mbeya, B; Rassool, M; Geiter, L; Cho, Y L; Heinrich, N.
Affiliation
  • Dierig A; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Munich, Germany.
  • Hoelscher M; German Center for Infection Research (DZIF), Munich partner site, Munich, Germany.
  • Schultz S; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Munich, Germany.
  • Hoffmann L; German Center for Infection Research (DZIF), Munich partner site, Munich, Germany.
  • Jarchow-MacDonald A; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Munich, Germany.
  • Svensson EM; German Center for Infection Research (DZIF), Munich partner site, Munich, Germany.
  • Te Brake L; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Munich, Germany.
  • Aarnoutse R; German Center for Infection Research (DZIF), Munich partner site, Munich, Germany.
  • Boeree M; Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, Munich, Germany.
  • McHugh TD; German Center for Infection Research (DZIF), Munich partner site, Munich, Germany.
  • Wildner LM; Ninewells Hospital and Medical School, NHS Tayside, Dundee, UK.
  • Gong X; Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Phillips P; Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Minja LT; Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Ntinginya N; Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Mpagama S; Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Liyoyo A; Division of Infection & Immunity, UCL Centre for Clinical Microbiology, University College of London, London, UK.
  • Wallis RS; Division of Infection & Immunity, UCL Centre for Clinical Microbiology, University College of London, London, UK.
  • Sebe M; Department of Medicine, Division of Pulmonary & Critical Care Medicine, University of California San Francisco, San Francisco, USA.
  • Mhimbira FA; Department of Medicine, Division of Pulmonary & Critical Care Medicine, University of California San Francisco, San Francisco, USA.
  • Mbeya B; National Institute for Medical Research, Mbeya Medical Research Centre (NIMR-MMRC), Mbeya, Tanzania.
  • Rassool M; National Institute for Medical Research, Mbeya Medical Research Centre (NIMR-MMRC), Mbeya, Tanzania.
  • Geiter L; Kilimanjaro Clinical Research Institute, Kilimanjaro, Tanzania.
  • Cho YL; Kilimanjaro Clinical Research Institute, Kilimanjaro, Tanzania.
  • Heinrich N; The Aurum Institute, Tembisa, South Africa.
Trials ; 24(1): 382, 2023 Jun 06.
Article in En | MEDLINE | ID: mdl-37280643
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis, Pulmonary / Oxazolidinones Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Adult / Humans Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2023 Type: Article Affiliation country: Germany
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis, Pulmonary / Oxazolidinones Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Adult / Humans Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2023 Type: Article Affiliation country: Germany